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A local defense mechanism in bacterial meningitis was evaluated in humans by measur-
ing complement-mediated opsonic activity (CMOA) in normal and infected cere-
brospinal fluid (CSF) with a complement-dependent phagocytic bactericidal assay. 
CMOA was absent in normal untreated CSF and remained undetectable in 20 samples 
of CSF from patients with viral meningitis and five samples from patients with acute 
meningococcemia. In contrast, 15 of 27 samples of CSF from patients with acute 
bacterial meningitis had a measurable CMOA, which was correlated with protein con-
centrations (P< 0.01) and C4 hemolytic activity (P< 0.001) in the CSF. A favorable out-
come of bacterial meningitis was associated with the presence of CMOA in CSF (P 
< 0.005). Recovery was also correlated with higher levels of C4 (P < 0.01) and C3 (P 
< 0.05) in CSF and with lower concentrations of microorganisms in the sample of CSF 
collected at the time of admission (P< 0.01). Thus, CMOA, although absent in normal 
CSF, can appear in CSF during acute bacterial meningitis, particularly in patients who 
recover completely. 
Mortality and morbidity from acute bacterial 
meningitis are still high despite substantial prog-
ress in diagnosis and treatment [1-3]. The devel-
opment and course of meningeal infection are 
governed by the complex interaction of many vari-
ables [4], including (1) microbial virulence factors 
such as encapsulation [5, 6], (2) clearance of bac-
teria from the blood [7-9], (3) antibacterial mech-
anisms in the subarachnoid space [10], (4) 
anatomic and functional changes resulting from 
inflammation [11, 12], and (5) antibiotic therapy. 
Because bacterial meningitis is in essence a closed-
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space infection, local defense mechanisms may be 
important factors that limit bacterial growth. Nor-
mal cerebrospinal fluid (CSF) can be considered as 
a site of a "local defect in host defense," because it 
contains no phagocytic cells, has a low protein 
concentration with a predominance of albumin 
[13], contains no IgM, and has low levels of C3 
and C4 [14-16]. Furthermore, recent studies have 
suggested that neither CH50 (the amount of com-
plement required to lyse 50070 of sensitized ery-
throcytes) nor overall bactericidal and opsonic 
activities are detectable in normal CSF [17, 18]. As 
a result, seeding of the CSF with> 103 organisms 
overcomes the clearance mechanisms of the CSF 
and leads to a rapid multiplication of the micro-
organisms [19]. Thus, CSF from patients with 
meningitis often yields initial bacterial counts of 
1 OL 1 08 bacterial ml; the higher values are asso-
ciated with clinical complications [20]. Once 
established, bacterial meningitis initiates inflam-
matory reactions in the CSF that result in the gen-
eration of chemotactic factors [21, 22] and in the 
appearance of CH50 activity [18], various classes of 
immunoglobulins [23, 24], and polymorphonu-
clear leukocytes (PMNLs), all of which would be 
expected to improve the local host defense 
mechanisms. 
Effective opsonization of bacteria by comple-
ment and immunoglobulin is an essential step for 
phagocytosis by PMNLs [25]. Thus, in susceptible 
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Opsonic Activity in CSF 637
subjects, complement-mediated opsonization may
playa crucial role during the early phase of men-
ingitis when specific antimicrobial antibodies are
lacking in the serum and CSF.
In the present study we evaluate qualitative and
quantitative changes of complement-mediated op-
sonic activity (CMOA) in normal and infected
CSF and try to establish the relation of CMOA to
the course and outcome of bacterial meningitis.
CMOA and complement levels were measured in
the CSF and plasma from uninfected control pa-
tients and from patients with viral meningitis.
Materials and Methods
Patients. Patients who had a diagnostic spinal
tap at the University Hospital, Geneva, were pro-
spectively included in the study. Conditions for ac-
ceptance were (1) an unequivocal diagnosis based on
clinical findings and a CSF sample; (2) availability
of a CSF sample from a spinal tap immediately
after admission; (3) absence of contamination of
the CSF sample by blood, as demonstrated by an
erythrocyte count of <200 cells/mm' and/or a
negative hemoglobin test (Labstix'"; Diethelm Co.,
Zurich) that detected an admixture of blood in
CSF at a dilution of 1:25,000; (4) delay of <6 hr
between lumbar puncture and freezing of the CSF
(median, 1.5 hr; range, 1-6 hr); and (5) absence of
degenerative or demyelinating disease of the cen-
tral nervous system and absence of spinal sub-
arachnoid block. The patients were divided into
four groups.
Group 1 consisted of patients with normal CSF.
Samples of CSF were taken from 10 patients who
had an acute, self-limited, febrile illness and from
15 afebrile patients with suspected disk herniation
who underwent diagnostic gas myelography and
had normal neuroradiologic findings. Each sam-
ple of CSF in this group had a normal protein con-
centration and a normal cell count. A CSF pool of
15 ml was obtained from a third cohort of 24 nor-
mal patients who had spinal anesthesia for
surgery.
Group 2 consisted of 20 patients who had viral
meningitis; these patients all had a febrile, self-
limited disease with signs of meningeal infection
that subsided without antibiotic treatment. The
patients ranged in age from three to 88 years (me-
dian, 29 years). The delay between the onset of
symptoms and the diagnostic lumbar puncture
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ranged from 18 to 240 hr (mean, 96 hr). Viral cul-
tures and serologic studies were not routinely per-
formed, but bacterial cultures of CSF and blood 
were consistently negative. CSF in this group was 
characterized by a median leukocyte count of 120 
cells/mm3 with a predominance of lymphocytes, a 
normal glucose level, and a moderate increase in 
protein concentration (mean, 45 mg/loo ml; range, 
20-76 mg/l00 ml). 
Group 3 consisted of five patients (nos. 28-32) 
who had fulminant meningococcemia - that is, sep-
tic shock, petechiae, disseminated intravascular 
coagulation, and presence of Neisseria meningi-
tidis both in blood and CSF (table 1). One patient 
died and one was discharged with permanent 
neurologic sequelae - that is, ataxia and left-sided 
hemiparesis. The patients' ages ranged from seven 
to 64 years. Despite CSF cultures that were posi-
tive for N. meningitidis, these patients had mini-
mal inflammation of CSF, as evidenced by a low 
leukocyte count (mean, 38 cells/mm3), normal 
protein concentration, and normal glucose level. 
Group 4 consisted of 27 patients (nos. 1-27) 
who had bacterial meningitis (table 1). Their ages 
ranged from two to 81 years (median, 25 years). 
The delay between the onset of symptoms and 
hospital admission ranged from 12 to 120 hr 
(mean, 39 hr). Samples of CSF included in the 
study were always obtained during the first lum-
bar puncture and were stored within a median 
time of 90 min. Pertinent clinical and bacterio-
logic data and CSF findings are listed in table 1. 
Of this group, 20 patients recovered completely, 
five survived with neurologic sequelae (cauda 
equinea syndrome, hydrocephalus, ataxia, and 
palsy due to cranial nerve damage), and two died 
of extensive brain damage. 
CSF and blood. To minimize in vitro comple-
ment activation, all CSF samples were collected 
and mixed in tubes that contained EDT A (final 
concentration, 5 mM) and were centrifuged at 
1,500 g for 15 min; the supernatants were stored 
immediately at -70 C. To obtain serum, blood 
was allowed to clot at room temperature (1"\.120 C) 
for 60 min, and serum was separated by centrifu-
gation at 1,500 g for 15 min and stored at - 70 C. 
To obtain plasma, blood was collected in tubes 
that contained EDT A (final concentration, 20 
mM) and centrifuged; the supernatant was imme-
diately stored at -70 C. Protein concentrations 
were measured in all of the samples of CSF and 
sera by the Bio-Rad protein assay (Bio-Rad Labo-
Zwahlen et al. 
ratories, Munich). A pool of normal human serum 
that was obtained from 20 donors was used as a 
standard. All samples were tested in duplicate. 
Samples of blood and CSF were cultured, and the 
microorganisms were identified by standard bac-
teriologic techniques [26]. Quantitative cultures 
were obtained from the CSF of 15 patients with 
bacterial meningitis and one patient with menin-
gococcemia according to the method described by 
Feldman [27]. 
Measurements of CMOA in CSF and serum. 
Preparation of CSF and serum samples. Before 
being used in the phagocytic assay, each sample of 
CSF or serum was diluted and reconcentrated 
three times in an ultrafiltration device with an ex-
clusion limit of 10,000 daltons (model no. PTGC 
001-K5; Millipore Corp., Kloten, Switzerland). 
This procedure, carried out at 4 C, was used to 
eliminate EDT A and to concentrate the immuno-
globulins and complement components in Dulbec-
co's phosphate-buffered saline (pH 7.4; Grand 
Island Biological Co., Basel, Switzerland). 
CMOA was not eliminated by this ultrafiltra-
tion procedure as demonstrated by the following 
experiment: six samples of 1 % normal human 
serum were submitted either to three consecutive 
dilution-concentration cycles or to no manipula-
tion; we observed a slight and reproducible loss of 
CMOA of 44% ± 120/0 (mean ± sD)-that is, less 
than one dilution - when CMOA was evaluated in 
a phagocytic assay. Similarly, for one patient (no. 
22) with bacterial meningitis, a sample of CSF that 
was obtained before the onset of antibiotic 
therapy was studied for CMOA before and after 
the dilution-concentration procedure; the samples 
showed 50% killing (K50) opsonic titers of 19.8 
and 11. 9 units/ml, respectively - that is, a loss of 
40% in opsonic activity after manipulation. Fur-
thermore, no increase of C3d was detected in ul-
trafiltered plasma. There was no residual anti-
biotic activity in ultrafiltered samples of serum or 
CSF as tested by agar diffusion [26] against 
Staphylococcus aureus variant strain Wood 46. 
Preparation of PMNLs. Leukocytes from 
healthy volunteers were separated from citrated 
blood by dextran sedimentation. The leukocytes 
were washed twice and suspended in phosphate-
buffered saline at a concentration of 1.25 x 107 
PMNLs/ml. 
Phagocytic bactericidal assay. The CMOA of 
the samples was evaluated by a modified phagocy-
tic bactericidal assay [28] using the Wood 46 strain 
Opsonic Activity in CSF 
of S. aureus. As outlined by Lew et al. [29], strain 
Wood 46 depends entirely on complement for its 
opsonization, and no significant phagocytosis or 
killing occurs in serum that has been inactivated 
by heating to 56 C for 30 min. Ingestion and 
killing of the test strain, however, are optimal 
(>90070 of the inoculum) in the presence of either 
normal, agammaglobulinemic, C3-deficient, or 
Mg2EGTA-treated 10070 serum. For each 0.5-ml 
assay, an aliquot of 0.05 ml of bacteria (3 x 106 
bacteria/ml) was added to a mixture of 0.4 ml of 
purified leukocytes (5 x 106 PMNLs/ml) and 0.05 
ml of serially diluted CSF or serum. The cell 
suspensions were incubated at 37 C in a shaking 
water bath, and duplicate samples of the test sus-
pension were drawn at time 0 and after incubation 
for 30 min. The samples were diluted, and the 
PMNLs were osmotically lysed with distilled 
sterile water and plated on Mueller-Hinton agar; 
the number of residual bacterial colonies was 
counted after incubation for 24 hr. Each of the 
samples was tested with two controls: (1) heat-
inactivated serum or CSF with PMNLs and (2) 
serum or CSF without PMNLs. 
Definition of the K50 opsonic titers. The Kso 
opsonic titer (expressed in units/ml) was defined 
as the inverse of the dilution of serum or CSF that 
promoted 50070 killing of S. aureus strain Wood 46. 
Measurements of complement factors in CSF 
and plasma. CHso was measured in a continuous 
flow system [30]. C4 hemolytic activity was also 
tested in a continuous flow system using the 
plasma of C4-deficient guinea pigs as a source of 
the other complement components in excess 
amount [31]. The activity of plasma factor B was 
assessed by lysis of 51 Cr-Iabeled rabbit erythro-
cytes in the presence of serum devoid of functional 
factor B activity [32] and was expressed in 
units/ml. C3 and C3d levels were measured by im-
munodiffusion [33, 34], using monospecific anti-
sera (Behringwerke, Marburg-Lahn, Federal Re-
public of Germany). The levels of the various 
complement components were measured in dupli-
cate and were expressed as percentages of the 
levels obtained with a pool of reference standard 
plasma. 
Samples of normal or infected CSF, which were 
stored in EDT A, were assessed for C4 hemolytic 
activity as well as for levels of C3 and C3d. The 
techniques that were used to test plasma were used 
for CSF measurements, but the sensitivity of the 
assays was increased by using lower dilutions of 
639 
the samples. The levels of the CSF complement 
factors were expressed as percentages of those of 
the pool of standard plasma. 
Statistical evaluation. Statistical tests were 
chosen according to Meddis [35]. Differences be-
tween groups were assessed by Student's unpaired 
t-test. Linear correlation coefficients were 
calculated by a standard program. Mean dose re-
sponse curves (figure 1) were calculated using the 
equation described by Wagner [36]. 
Results 
CMOA in normal CSF and sera. Normal CSF 
had to be concentrated in order to exhibit CMOA, 
100 
50 
-;. 
OJ 
C 
.... 
~ 
0 
C1 12,5 25 50 100 200 400 Qj 
U 
C1 
m 100 
12,5 25 50 100 200 400 
Protein concentration (mg 1100ml) 
Figure 1. Heat-labile opsonic activity in (0) human 
cerebrospinal fluid (CSF) and (.) serum. The results 
show the effects of protein concentration in the opsonic 
source (untreated, concentrated, or diluted CSF and di-
luted sera) on the percentage of killing of Staphylococ-
cus aureus variant strain Wood 46. Mean dose-response 
curves were calculated for ( - - - ) CSF and (-) serum: 
(top) 15 samples of CSF and paired sera from subjects 
without meningitis; (bottom) 15 samples of CSF and 
paired sera from patients who had acute bacterial men-
ingitis and measurable opsonic activity. 
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because neither diluted nor undiluted samples of 
CSF were able to opsonize S. aureus strain Wood 
46 (table 2). Addition of purified IgO (3 mg/ml) 
or 100/0 heat-inactivated serum to untreated CSF 
did not promote opsonization of the test bacteria. 
In contrast, a 10-fold concentration of 15 samples 
of normal CSF obtained during gas myelography 
(when tested at a final mean [± SD] protein con-
centration of 354 ± 135 mg/100 ml) allowed for 
detection of a heat-labile opsonic activity compa-
rable to that of 100/0 normal serum. Further evi-
dence for the complement-mediated nature of this 
opsonic activity was obtained by testing the sam-
ple of CSF that was taken at the time of admission 
from an agammaglobulinemic patient who had 
acute meningococcal meningitis (patient no. 5). 
When tested at a protein concentration of 296 
mg/ 100 ml, this sample of CSF promoted 650/0 
bacterial killing. 
The relationship between CMOA, expressed as 
the percentage of bacteria that were killed, and 
protein concentration in CSF was further studied 
in the group of 15 samples of normal concentrated 
CSF referred to above. A sigmoidal relationship 
was observed when the 16-fold concentrated sam-
Table 2. Opsonization of Staphylococcus aureus 
variant strain Wood 46 by human cerebrospinal fluid 
(CSF) and serum in a phagocytic bactericidal assay. 
Source of opsonic 
activity, treatment 
CSF 
Normal, 10% dilution 
Normal, 500/0 dilution 
Normal, untreated 
Normal, 1O-fold concentration 
Normal, 1O-fold concentration, 
heatedt 
Agammaglobulinemic, 50% 
Percentage 
of bacterial No. of 
killing * experiments 
o 
o 
o 
66-97 
0-2 
10 
25 
15 
15 
3 
dilutiont 65 
Serum 
Normal, 10% dilution 
Normal, 10% dilution, 
heatedt 
Agammaglobulinemic, 10% 
90-99 
0-5 
dilution 72 
10 
10 
* Percentage of initial inoculum killed after 30 min of in-
cubation. Data are ranges when more than one experiment 
were performed. 
t Heated at 56 C for 30 min. 
t This sample of CSF was obtained from a patient with acute 
meningitis and was tested at a protein concentration similar to 
that of normal CSF at a 1O-fold dilution. 
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Figure 2. Complement-mediated opsonic activity 
measured in the cerebrospinal fluid (CSF) of 25 control 
patients and patients with viral meningitis (14 patients), 
meningococcemia (five), or bacterial meningitis (27). 
Clinical outcome was reported as (0) complete 
recovery, (~) recovery with neurologic sequelae, or (.) 
death. The horizontal line represents the- detection level 
of opsonic activity with the assay used; the first CSF 
dilution tested was 1 :2. Kso opsonic titers were defined as 
the inverse of the dilution of serum or CSF that pro-
moted 50070 killing of Staphylococcus aureus variant 
strain Wood 46 (see Materials and Methods). 
pIes of CSF were serially diluted to the normal 
range of protein concentration in the CSF (figure 
1, top). A similar sigmoidal curve was also ob-
served when sera from the same patients were 
serially diluted, but the levels of bacterial killing 
increased at lower protein concentrations when 
compared with the samples of CSF (P < 0.001). 
Normal CSF had to be concentrated an average of 
4.2 times to kill 50% of the test bacteria. Thus, the 
mean (± sn) Kso opsonic titer of the 15 samples of 
CSF was estimated at 0.242 ± 0.122 units/ml of 
untreated CSF. By comparison, the mean Kso op-
sonic titer in the paired sera was 151 ± 38 
units/m!. When adjusted for protein concentra-
tion, 1 mg of CSF protein corresponded to 0.82 ± 
0.33 Kso opsonic units as compared with 2.12 ± 
0.64 units in 1 mg of serum protein (P < 0.001). 
When CMOA was expressed in Kso units, we 
found a linear correlation of this parameter with 
the CSF protein concentration (r = 0.68; P 
< 0.001). CHso was also assayed in 10 of the 15 
samples of concentrated CSF and was found to be 
positively correlated with the Kso opsonic titers (r 
= 0.70; P < 0.02). 
CMOA in inflammatory CSP. The most strik-
ing variations in the CMOA of CSF were observed 
in group 4 (bacterial meningitis) patients (figure 
2). Because of the small volumes of the samples 
from patients with meningitis, CMOA could only 
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be estimated at an initial CSF dilution of 1 :2. At 
this dilution, group 1 (control patients), group 2 
(patients with viral meningitis), and group 3 (pa-
tients with meningococcemia) showed complete 
absence of CMOA. In contrast to these results, 15 
of 27 patients in group 4 had evidence of CMOA 
in their CSF. When further tested at serial dilu-
tions, the CMOA-positive samples of CSF had K50 
opsonic titers ranging from 2.4 to 18.5 units (mean 
± SD, 8.13 ± 5.45). These Kso titers of CSF were 
not significantly correlated with Kso titers in the 
corresponding sera but were correlated with the 
protein concentrations in inflammatory CSF (r = 
0.56; P< 0.01) (figure 3). Several samples of CSF, 
however, had undetectable levels of CMOA in 
spite of a marked increase in their protein concen-
tration. The relationship between protein concen-
tration and CMOA was further tested in the 15 
CMOA-positive samples of CSF from patients 
with bacterial meningitis and exhibited a sigmoi-
dal dose-response curve (figure 1, bottom) as 
noted above for normal CSF (figure 1, top). In 
contrast to the normal curve, there was no shift of 
the inflammatory CSF curve. Because 1 mg of 
CSF protein contained 1.81 ± 0.84 (mean ± SD) 
Kso opsonic units vs. 2.0 ± 0.94 units/mg of 
serum protein (difference not significant), we con-
cluded that the inflammatory process observed in 
15 of 27 patients with bacterial meningitis restored 
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Figure 3. Opsonic activity measured in the cerebrospi-
nal fluid (CSF) of 27 patients who had bacterial men-
ingitis; results are expressed as a function of the protein 
concentration in CSF. Clinical outcome is reported as 
(0) complete recovery, «(j) recovery with neurologic se-
quelae, or ( • ) death. The horizontal line represents the 
detection level of opsonic activity with the assay used; 
the first CSF dilution tested was 1 :2. 
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Figure 4. Levels of complement components in the 
cerebrospinal fluid (CSF) of control patients and pa-
tients who had viral meningitis, meningococcemia, or 
bacterial meningitis. The percentages of activity or con-
centration of complement in pooled normal plasma are 
shown for (top) C4 hemolytic activity, (middle) C3 con-
centrations, and (bottom) C3d concentrations. Patients 
with bacterial meningitis were divided into (a) those who 
had detectable and (b) those who had undetectable levels 
of opsonic activity in the CSF. Detectable levels of op-
sonic activity were defined as K~o opsonic titers (the in-
verse of the dilution of CSF that promoted 500/0 killing 
of Staphylococcus aureus variant strain Wood 46) of ~2 
units/ml. Horizontal lines show averages of comple-
ment levels for each group of patients. 
the levels of CMOA observed in samples of unin-
fected CSF to those observed in serum. 
CSF complement factors were assayed in the 
four groups of patients (figure 4); patients from 
group 4 were divided into two subgroups accord-
ing to whether their CSF was CMOA-positive or 
-negative. A striking increase of C4 hemolytic ac-
tivity was observed in the CMOA-positive samples 
of CSF from patients with bacterial meningitis as 
compared either with CMOA-negative CSF or with 
CSF obtained in the other three groups (P 
< 0.001). C4 activities in the CSF of patients in 
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Table 3. Heat-labile opsonic activity (K 50), hemolytic activity of complement, and concentrations of complement 
components in sera and plasma from normal control patients and patients with acute meningitis. 
Control patients Viral Meningococcemia Bacterial 
Complement factors (n = 20) meningitis (n = 18) (n = 5) meningitis (n = 26) 
K50 opsonic titers* 
Experimental valuest 151 ± 38 156 ± 92 52 ± 34t 104 ± 46+ 
Values adjusted for 
protein concentration§ 2.12 ± 0.64 2.63 ± 1.7 0.96 ± 0.88+ 2.00 ± 0.96 
Hemolytic activity of 
cH 5oll# 96 ± 20 124 ± 27t 52 ± 20+ 110 ± 24 
C4# 99 ± 27 85 ± 22 77 ± 39 91 ± 46 
Factor Bt 58 ± 18 54 ± 18 39 ± 19 59 ± 21 
Concentration of 
C3** 96 ± 17 100 ± 13 54 ± 34+ 121 ± 22+ 
C3d** 5 ± 8 13 ± 7 33 ± 22+ 31 ± 25+ 
Total proteintt 73 ± 9 65 ± 7t 54 ± 9t 56 ± 9t 
NOTE. Data are means ± SD; n = no. of patients tested. 
* The inverse of the dilution that promoted 500/0 killing of Staphylococcus aureus variant strain Wood 46. 
t Expressed as units/ml. 
t Differs significantly from control values (P < 0.01). 
§ Expressed as units/mg. 
II Total hemolytic activity of complement. 
# Expressed as the percentage of activity in pooled normal serum. 
** Expressed as the percentage of concentration in pooled normal serum. 
tt Expressed as g/liter. 
group 4 showed a close correlation with CSF K50 
opsonic titers (r = 0.79; P< 0.001) and with CSF 
protein concentrations (r = 0.59; P < 0.005). 
CMOA-positive samples of CSF also showed an 
increase in their immunochemically measured 
levels of C3 as compared with CMOA-negative 
samples of CSF (P < 0.02). C3d, the breakdown 
product of C3, was demonstrated in eight CMOA-
positive samples and in one CMOA-negative sam-
ple of CSF but was never detected in the CSF from 
patients in groups 1, 2, or 3. Levels of C3d in CSF, 
when expressed per milligram of protein, were 
three to 48 times higher than the protein-adjusted 
levels of C3d in plasma obtained from the same 
patients. Thus, the presence of measurable levels 
of CMOA in CSF of patients with bacterial men-
ingitis is associated with an increase of C4 activity 
and C3 level and with evidence of local activation 
of C3. 
Serum CMOA and plasma complement levels 
were measured in the four groups of patients to 
learn whether the local changes in the CSF during 
bacterial infection resulted from simultaneous 
modifications in the plasma (table 3). Definite 
changes were observed in the plasma of patients 
who had fulminant meningococcemia: lower levels 
of K50 opsonic titers (P < 0.01), CHso (P < 0.001), 
and factor B activities (P < 0.05) and higher levels 
of C3d (P< 0.01) when compared with control pa-
tients (group 1). Levels of C3d also increased in 
the plasma of patients with bacterial meningitis 
when compared with group 1 subjects (P < 0.01). 
No correlation was found between the levels of 
either component in paired samples of CSF and 
plasma. 
Correlation between opsonic activity of CSF 
and clinical course of bacterial meningitis. Among 
the 27 patients with bacterial meningitis, 20 re-
covered completely, two died from the disease, 
and five developed permanent neurologic se-
quelae. All of the 15 patients who had measurable 
levels of CMOA in their CSF recovered complete-
ly from the disease, whereas all seven patients who 
had neurologic sequelae or a lethal outcome were 
among the 12 patients who had undetectable levels 
of opsonic activity in their CSF (table 4). There-
fore, the presence of CMOA in the CSF from pa-
tients with bacterial meningitis was correlated with 
a favorable clinical outcome (P < 0.005; Fisher's 
exact test). Complete recovery was also associated 
with a higher mean C4 hemolytic activity in CSF 
(P < 0.001), with higher C3 levels (P < 0.05), and 
with a lower mean bacterial count in the sample of 
CSF taken at the time of admission (P < 0.001) 
(table 5). No significant differences could be ob-
served in the mean protein concentration or in the 
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Table 4. Clinical outcome in patients with bacterial 
meningitis and the presence of measurable opsonic ac-
tivity in cerebrospinal fluid (CSF). 
Opsonic activity 
Present 
Absent 
Total 
Clinical outcome 
(no. of patients) 
Complete Sequelae 
recovery or death 
15 0 
5 7 
20 7 
Total no. 
of patients 
15 
12 
27 
NOTE. Samples of CSF were tested first at a dilution of 
1 :2, which corresponded to an opsonic activity of ~2 Kso (50nJo 
killing) units/ml. The association between complete recovery 
and the presence of opsonic activity in CSF is statistically 
significant (P < 0.005 by Fisher's exact test). 
mean PMNL counts in CSF between the two 
groups of patients. Patient groups with a 
favorable or unfavorable clinical course had 
similar plasma K50 opsonic titers and complement 
levels; further analysis of the various clinical data 
failed to reveal a significant association of neuro-
logic complications or death with age, sex, dura-
tion of symptoms prior to the start of antibiotic 
therapy, bacteremia on admission, or presence of 
a particular etiologic agent. 
Discussion 
The rationale for studying CMOA in normal and 
infected CSF resides in the fact that in nonimmune 
patients, opsonically active complement is one of 
the first defense mechanisms against pathogenic 
organisms [37, 38] and might contribute to host 
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defense at an early phase of bacterial meningitis 
when specific antibodies are still lacking. The data 
presented above demonstrate that CMOA was un-
detectable in normal untreated CSF but was mea-
surable after concentration; levels of CMOA also 
remained undetectable in the unconcentrated CSF 
of patients who had viral meningitis or fulminant 
meningococcemia at an early stage of the disease 
when noninflammatory CSF was already culture-
positive. In contrast, CMOA appeared in 15 of 27 
samples of CSF obtained during the early phase of 
bacterial meningitis, and its presence was corre-
lated with a favorable clinical outcome. Such a 
favorable clinical evolution was also associated 
with an increase in complement levels and with 
lower concentrations of infecting microorganisms 
in CSF. 
Several methodologic aspects of the technique 
used in this study should be discussed. In our pha-
gocytic assay we did not use encapsulated bacteria 
causing meningitis as biological effectors; we used 
S. aureus strain Wood 46 because we wanted to 
measure early, nonspecific, functional CMOA in 
CSF, rather than individual immune response to 
specific microorganisms in nonimmune patients. 
Furthermore, it is generally accepted that bacterial 
meningitis develops only in patients who lack 
type-specific, functional serum antibodies [39]. It 
is therefore likely that the study of early, specific 
immune response in CSF to the offending orga-
nisms would have given negative results. For ethical 
reasons, the phenomenon of the time-dependent 
appearance of specific antibodies can only be ex-
amined in an animal model. Previous studies in 
our laboratory have shown that the opsonization 
Table 5. Correlation of clinical outcome in patients with bacterial meningitis and K50 (50070 killing) opsonic titers, 
complement levels, and bacterial counts in cerebrospinal fluid (CSF). 
Complete recovery Sequelae or death Association with 
CSF factors (n = 20) (n = 7) recovery 
Kso opsonic titers (units/ml)* 6.1 ± 5.91 <2 P< 0.005 
C4 hemolytic activityt 1.12 ± 0.90 0.15 ± 0.13 P < 0.01 
Concentration of C3 t 0.50 ± 0.34 0.32 ± 0.19 P< 0.05 
Bacterial counts (log cfu/mI)t 5.11 ± 1.16 7.22 ± 0.75 P < 0.001 
Protein concentration (mg/100 ml) 372 ± 268 160 ± 74§ NS 
NOTE. Data are means ± SD and probabilities of association with recovery calculated by Fisher's exact test. NS = not 
significant. 
* Kso = the inverse of the dilution of CSF that promoted 50070 killing of Staphylococcus aureus variant strain Wood 46. 
t Expressed as the percentage of activity or concentration in pooled normal serum. 
t Performed in samples from 10 patients who recovered and from five patients who either died or had sequelae. 
§ Mean calculated for six of the seven patients who either died or had sequelae; patient no. 23 was excluded because of an 
unusually high concentration of protein in the CSF (1,230 mgllOO mt). 
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of S. aureus strain Wood 46 by human serum 
depends mainly on the complement system, and 
the role played by antibody is minimal [29]. The 
results of the present studies, which use CSF as the 
source of opsonic activity, confirm the earlier data 
(table 2). The correlation found between CMOA 
and CHso in 10 samples of normal concentrated 
CSF (P < 0.02) and between CMOA and C4 ac-
tivities in samples of CSF from patients with men-
ingitis (P < 0.001) provides further evidence that 
the heat-labile opsonic activity in CSF that was 
measured by our phagocytic assay was indeed 
complement-mediated. 
The method used to obtain and store CSF 
samples for measurement of complement levels or 
opsonic activity turned out to be a crucial metho-
dologic point; spontaneous decay of complement 
occurs in untreated frozen CSF [15] and may even 
be accelerated when CSF that is taken from pa-
tients with systemic lupus erythematosus and cen-
tral nervous system involvement is stored at - 45 
C [40]. To minimize this problem, all samples of 
CSF were drawn into vials containing EDT A and 
were immediately frozen at -70 C. Blood con-
tamination of the CSF, which would have resulted 
in falsely high levels of complement activities, was 
eliminated by excluding all CSF samples with an 
admixture of blood of ~1:25,000. 
We started our study with the hypothesis that 
the phagocytic test developed by Lew et al. [29] 
could be adapted to untreated CSF because the 
mean Kso opsonic titers measured in pooled serum 
(236 units/ml) approximated the protein ratio 
found between normal untreated CSF and serum 
(1:250). However, CMOA was not detected in 
fresh undiluted CSF with this assay. By concen-
trating large volumes of normal CSF obtained 
during gas myelography, we were able to show 
that normal untreated CSF was devoid of CMOA. 
The absence of CMOA in CSF was evidenced by 
the low protein concentration in CSF; moreover, 
CMOA, expressed per milligram of protein, could 
be demonstrated to be lower in the CSF than in the 
serum from the same patient (figure 1, top). These 
findings are consistent with the data of Tofte et al. 
[17], who described an absence of opsonization of 
various encapsulated bacteria by normal CSF, 
whereas one sensitive strain of S. aureus (strain 
502A) was opsonized by esp. Our results are also 
in agreement with those published by Simberkoff 
et al. [18], who used various pathogenic and non-
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pathogenic test bacteria and showed no bacterici-
dal and no opsonic activity in normal CSF. 
Our experiments with concentrated CSF suggest 
that the opsonic defect is not qualitative but mere-
ly quantitative. Sensitization of the phagocytic test 
by ultrafiltration had the additional advantages of 
eliminating all potential traces of antibiotics and 
EDT A from the samples and allowing us to test 
CSF under native conditions but in a well-buffered 
system. To minimize any error introduced by 
manipulating the CSF, we systematically prepared 
each sample of CSF and serum by ultrafiltration 
shortly before use. Control experiments showed 
that the ultrafiltration-concentration procedure 
resulted in a minimal, reproducible loss of CMOA 
and was not accompanied by any evidence of com-
plement activation. 
Early appearance of CMOA in CSF during bac-
terial meningitis - as opposed to viral men-
ingitis - was paralleled by increases in C3 activity 
and C3 levels, which confirmed the presence of 
CHso [18] and various other complement com-
ponents [24, 41, 42] in the CSF of patients with 
meningitis. The early appearance of CMOA in 
CSF was further correlated with changes in the 
protein concentrations in CSF early in the course 
of the disease. Kso opsonic titers in the CSF, 
however, when adjusted for protein concentra-
tion, never exceeded Kso values in serum, which 
were also adjusted for protein concentration. It is 
therefore probable that the appearance of CMOA 
in CSF is one of the numerous changes induced by 
local inflammation of the subarachnoid space. 
The appearance of CMOA may be the result of an 
increase in the permeability of the blood-brain 
barrier for large molecules, as suggested by the ap-
pearance of IgM in infected CSF [23]. A part of 
complement is probably activated in the eSF dur-
ing meningitis, as evidenced by the presence of 
C3d, the breakdown product of C3, in the CSF of 
nine patients. 
The clinical relevance of the correlation found 
between the presence of CMOA in the CSF and a 
favorable clinical outcome for patients with bacte-
rial meningitis needs to be put in proper perspec-
tive. First, CMOA - as assessed by the phagocytic 
assay with S. aureus strain Wood 46 - does not 
measure possible specific opsonins in eSF and 
serum or the bactericidal defense mechanisms that 
each patient produces in response to the particular 
microorganism that causes the infection. How-
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ever, these factors are unlikely to be present ini-
tially and were undetectable in the CSF of patients 
with acute bacterial meningitis [18]. In contrast, 
complement activity - as measured in our assay-
is a nonspecific but immediately available host de-
fense factor [38], and its level in the CSF may be 
important in limiting the rate of bacterial growth, 
as shown under other conditions [25, 37, 43]. 
Also, it should be stressed that the association be-
tween the presence of CMOA in the CSF and a 
favorable outcome for patients with meningitis is 
purely descriptive and that the present data do not 
prove a causal relationship. In fact, we cannot ex-
clude the possibility that a common mechanism 
(for example, greater permeability of the blood-
CSF barrier for both complement components 
and antibiotics) simultaneously influences several 
factors. However, patients who recovered com-
pletely from meningitis not only had higher K50 
opsonic titers but also had lower mean initial bac-
terial counts in their CSF than did patients with 
complications, as previously observed by Feldman 
[20]. Thus, any mechanism that is able to moder-
ate bacterial growth in the CSF may be an impor-
tant determinant of the course of the disease and 
may allow the patient to receive medical therapy 
before complications arise. The possibility that 
CMOA in CSF might not merely reflect the per-
meability of the blood-meningeal barrier but may 
express an important biologic role of complement 
that is independent of the inflammatory process is 
illustrated by one subject in our study. Patient no. 
23 had fatal post-traumatic meningitis due to 
E. coli; his initial sample of CSF contained over 
108 cfu of bacteria/ml and had undetectable levels 
of C4, C3, and opsonic activity, in spite of a mas-
sive increase in protein concentration in the CSF. 
This situation was associated with very high levels 
of C3d, the breakdown product of C3, in the CSF. 
Thus, bacterial infection of the subarachnoid 
space may occasionally lead to a state of local con-
sumption of opsonins and complement as pre-
viously demonstrated for pleural empyema [29, 
44, 45]. 
Our results show that despite its barely detect-
able concentration in normal CSF, CMOA rapidly 
appears during the course of bacterial meningitis. 
The current results suggest that CMOA in CSF 
might be one of the numerous factors that influ-
ence the outcome of the disease. Increasing the 
level of opsonic activity in the CSF had already 
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been suggested in the preantibiotic era [46] as a 
means of influencing the outcome of bacterial 
meningitis, and this therapeutic strategy can now 
be evaluated in animal models. 
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